This site is intended for healthcare professionals only
Share this article

Pioglitazone and bladder cancer risk

Many general practices in the UK will have patients using the only remaining available PPAR-gamma agonist, pioglitazone, and so an independently funded study by the European Association for the Study of Diabetes is welcome. This study used a complex analysis to examine the effect of exposure to this drug on bladder cancer incidence. Based on a large observational analysis, the study authors concluded that the use of pioglitazone was not associated with an increased incidence of bladder cancer.

by Colin Kenny, GP, Dromore

The European Association for the Study of Diabetes commissioned this study from the Scottish Diabetes Research Network Epidemiology Group and the Diabetes and Cancer Research Consortium. The collaborators examined prescription, cancer and mortality data from people with type 2 diabetes in six populations across the world. The researchers observed that some of the existing data were contradictory and based on short time observations and that long-term data were needed.

The group collated data on 1.01 million persons over 5.9 million person-years. There were 3248 cases of incident bladder cancer, with 117 exposed cases, and a median follow-up duration of 4.0–7.4 years. Overall, the group found no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men or women after adjustment for age, diabetes duration and smoking.


To access the full publication, click here

Related content
Breastfeeding associated with lower CVD risk in high-risk women
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.